FDS — FactSet Research Systems Inc.

The market is genuinely split as of 2026-10-04. The Sept 30 FY26 Q4 beat and constructive FY27 guidance (margins framed as a 'floor') were positive, yet the shares fell 4.18% that day and 13.1% over the month - investors focused on GAAP EPS declining four straight quarters (4.06 → 3.59 → 3.51 → 3.41) and organic ASV growth guided down to 5.0-6.5% from 7.0%. Analyst consensus is 'Hold' (0 strong buy / 3 buy / 20 hold / 7 sell) with a $256.75 consensus target - essentially where the stock trades. The tug-of-war is between a sticky 95%+ retention, 7.5% free-cash-flow yield business and real fear that AI erodes the data-subscription moat.

Revenue is a metronome: steady ~6-7% YoY growth for three years, from $542M (Q1 FY24) to $635M (Q4 FY26), with no meaningful acceleration or deceleration quarter to quarter. The story is below the top line. Operating margin has compressed hard - from roughly 33% across FY25 quarters (33.6%, 32.5%, 33.2%, 29.7%) to 24.7% in Q4 FY26 - and GAAP diluted EPS fell four straight quarters (4.06 → 3.59 → 3.51 → 3.41). Note the Q4 FY24 GAAP dip to $2.32 was a one-off (the R&D line spiked to $266M that quarter vs. ~$0 elsewhere), not a trend. Meanwhile free cash flow is growing strongly: FY24 $614.7M → FY25 $617.5M → FY26 $707.5M. Read: stable top line, a deliberate investment-driven margin trough (management calls FY26 the floor), and rising cash generation - earnings quality is intact even as profitability optics deteriorate.

Cheap vs. its own history and cheap on cash flow - with an asterisk. At $266 the stock carries an 18.2x TTM GAAP P/E vs. a 5-year average of 30.4x, and about 13.5x forward adjusted EPS ($19.66). P/S is 3.82 vs. a 6.98 5-year average. The negative PEG (-2.54) is an artifact of the trailing GAAP EPS dip and isn't meaningful. A 7.5% FCF yield ($707M FCF / $9.46B cap) is generous for a 95%-retention subscription model. The tension: the low multiple is a value opportunity if the margin trough is cyclical, or a fair price if AI/competition makes mid-single-digit growth and margin recovery a permanent ceiling. On the numbers alone, the multiple embeds a lot of pessimism.

The de-rating from 30x to 18x means much of the bad news is already priced in - the stock is not being valued for growth that hasn't shown up. The asymmetry: if FY27 delivers the guided margin recovery and 6%+ ASV growth, EPS reaccelerates toward the $19.25-19.65 range and the multiple has room to re-rate modestly. If organic ASV slips below 5% or margins fail to recover, the 13.5x forward P/E and 7.5% FCF yield still provide a valuation cushion that limits downside. So this is less 'priced for perfection' and more 'priced for permanent stagnation' - the payoff skew hinges on whether the Nov 10 Investor Day confirms the margin floor and mid-term targets.

As of 2026-10-04, RSI(14) stood at 43.3 - neutral, edging weak, not oversold. Price sat 3.47% below the 20-day and 5.88% below the 50-day, but 6.79% above the 200-day: a short-term pullback inside a longer-term uptrend (6-month +16.8%). The month's -13.1% move has reset momentum without capitulating. Timing implication: no compelling technical entry signal yet - not oversold, no bounce. A stabilization near the 200-day, or RSI dipping toward the mid-30s with a reversal candle, would be a better entry trigger than chasing here.

• AI disruption vs. AI monetization: the same technology that threatens the traditional data-terminal moat is also a tailwind - AI drove 10%+ of Q4 new subscription value and 90%+ of top-50 clients use four-plus AI tools.
• Capital-markets activity and interest rates: high rates and muted deal/issuance activity squeeze buy-side and sell-side client budgets that feed FactSet's wallet share.
• Enterprise software/tech spending restraint: slower overall tech budgets keep pricing power and seat expansion under scrutiny even with 95%+ retention.
• Competitive intensity from Bloomberg, S&P Global, and LSEG/Refinitiv, capping both growth and multiple expansion.
• Multiples/rotation: data-and-analytics names have de-rated broadly, so FactSet's move from 30x to 18x partly reflects sector multiple compression rather than company-specific deterioration alone.

• Investor Day on Nov 10, 2026 - management to detail medium-term financial targets and its margin-recovery/AI roadmap; the key swing factor for the re-rating case.
• FY27 execution on the 'margin floor' and organic ASV growth of 5.0-6.5%; evidence of margin recovery would validate the cyclical-trough thesis.
• AI product monetization ramp and deepening Google Cloud / TIFIN.AI partnerships.
• Contribution from the Sept 22, 2026 BCC Group International acquisition (enterprise real-time market data).
• Buyback: $356M remaining authorization after repurchasing 552,064 shares for $138M in Q4 FY26.

• The margin compression proves structural (AI-driven disintermediation of the terminal/data model) rather than a deliberate investment-cycle trough.
• Organic ASV growth decelerates below the guided 5.0-6.5%, pressuring the already-de-rated multiple.
• Intensifying competition from Bloomberg, S&P Global, and LSEG on pricing and product breadth.
• Client budget cuts in a weak capital-markets/interest-rate environment.
• Integration and capital-allocation risk from M&A (BCC) against a balance sheet with $871M long-term debt and a thin 0.599 current ratio (largely a debt-reclassification artifact, but worth watching).

A high-quality, sticky subscription franchise (95%+ retention, 16% ROIC, 7.5% FCF yield) trading at a de-rated 18x TTM / ~13.5x forward after its multiple was cut roughly in half. The bear case - AI disruption and margin compression - is meaningfully in the price; the bull case rests on management's claim that FY26 margins are the floor and that AI is additive, not cannibalistic. This is a fair, not exceptional, business at a genuinely inexpensive-vs.-its-own-history price: a reasonable patient-holder setup with a slightly favorable skew, but not a high-conviction buy until the margin inflection is proven.

Applied ~15x to the FY2027E adjusted EPS midpoint of ~$19.5 (guidance $19.25-19.65) - a modest premium to the current ~13.5x forward but far below the 5-year average 30x P/E, reflecting a de-rated yet still high-quality subscription model - giving ~$292.50, then nudged to ~$295 to reflect a ~6.5% fair FCF yield cross-check on ~$707M FY26 FCF (≈$306/share).